ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Position Decreased by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. cut its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 25.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 588,874 shares of the biotechnology company’s stock after selling 202,917 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in ADMA Biologics were worth $11,772,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Assenagon Asset Management S.A. grew its holdings in shares of ADMA Biologics by 2.7% during the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares in the last quarter. Seven Eight Capital LP purchased a new position in ADMA Biologics during the 2nd quarter valued at about $1,992,000. Principal Financial Group Inc. lifted its position in ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after buying an additional 1,059,394 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of ADMA Biologics in the third quarter worth $2,253,000. Finally, Point72 Asset Management L.P. purchased a new stake in shares of ADMA Biologics during the second quarter worth $1,157,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Down 0.3 %

ADMA opened at $21.30 on Friday. The firm has a market cap of $5.04 billion, a P/E ratio of 76.07 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The business has a 50 day moving average price of $18.72 and a 200 day moving average price of $14.69. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period last year, the business posted $0.01 EPS. Research analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HC Wainwright upped their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th.

Insider Transactions at ADMA Biologics

In other news, Director Jerrold B. Grossman sold 136,861 shares of the business’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the transaction, the director now owns 467,305 shares in the company, valued at approximately $8,070,357.35. The trade was a 22.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares of the company’s stock, valued at $2,843,290.27. This represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 406,900 shares of company stock worth $7,128,521. Company insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.